Biopharmaceutical company Immuron Ltd
(ASX:IMC) has appointed biotechnology executive Joe Baini as the company’s new chief executive officer.
Immuron’s current CEO, Dr Grant Rawlin, has been appointed has chief scientific officer and will be responsible for managing the clinical trials, influenza projects and the firms’ overall platform technology.
The appointments are effective immediately.
For the year ended 30 June 2010, Immuron reported a net loss of $1.9 million.
